Cargando…

Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy

BACKGROUND: Research is revealing the complex coordination between cell signaling systems as they adapt to genetic and epigenetic changes. Tools to uncover these highly complex functional linkages will play an important role in advancing more efficacious disease treatments. Current tumor cell signal...

Descripción completa

Detalles Bibliográficos
Autores principales: MacNeil, Ian A., Khan, Salmaan A., Sen, Adrish, Soltani, Sajjad M., Burns, David J., Sullivan, Brian F., Laing, Lance G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742957/
https://www.ncbi.nlm.nih.gov/pubmed/34998412
http://dx.doi.org/10.1186/s12964-021-00798-9
_version_ 1784629811253084160
author MacNeil, Ian A.
Khan, Salmaan A.
Sen, Adrish
Soltani, Sajjad M.
Burns, David J.
Sullivan, Brian F.
Laing, Lance G.
author_facet MacNeil, Ian A.
Khan, Salmaan A.
Sen, Adrish
Soltani, Sajjad M.
Burns, David J.
Sullivan, Brian F.
Laing, Lance G.
author_sort MacNeil, Ian A.
collection PubMed
description BACKGROUND: Research is revealing the complex coordination between cell signaling systems as they adapt to genetic and epigenetic changes. Tools to uncover these highly complex functional linkages will play an important role in advancing more efficacious disease treatments. Current tumor cell signal transduction research is identifying coordination between receptor types, receptor families, and transduction pathways to maintain tumor cell viability despite challenging tumor microenvironment conditions. METHODS: In this report, coactivated abnormal levels of signaling activity for c-Met and HER family receptors in live tumor cells were measured by a new clinical test to identify a subpopulation of breast cancer patients that could be responsive to combined targeted therapies. The CELsignia Multi-Pathway Signaling Function (CELsignia) Test uses an impedance biosensor to quantify an individual patient’s ex vivo live tumor cell signaling response in real-time to specific HER family and c-Met co-stimulation and targeted therapies. RESULTS: The test identified breast tumors with hyperactive HER1, HER2, HER3/4, and c-Met coordinated signaling that express otherwise normal amounts of these receptors. The supporting data of the pre-clinical verification of this test included analyses of 79 breast cancer patients’ cell response to HER and c-Met agonists. The signaling results were confirmed using clinically approved matching targeted drugs, and combinations of targeted drugs in addition to correlative mouse xenograft tumor response to HER and c-Met targeted therapies. CONCLUSIONS: The results of this study demonstrated the potential benefit of a functional test for identifying a subpopulation of breast cancer patients with coordinated abnormal HER and c-Met signaling for a clinical trial testing combination targeted therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00798-9.
format Online
Article
Text
id pubmed-8742957
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87429572022-01-10 Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy MacNeil, Ian A. Khan, Salmaan A. Sen, Adrish Soltani, Sajjad M. Burns, David J. Sullivan, Brian F. Laing, Lance G. Cell Commun Signal Research BACKGROUND: Research is revealing the complex coordination between cell signaling systems as they adapt to genetic and epigenetic changes. Tools to uncover these highly complex functional linkages will play an important role in advancing more efficacious disease treatments. Current tumor cell signal transduction research is identifying coordination between receptor types, receptor families, and transduction pathways to maintain tumor cell viability despite challenging tumor microenvironment conditions. METHODS: In this report, coactivated abnormal levels of signaling activity for c-Met and HER family receptors in live tumor cells were measured by a new clinical test to identify a subpopulation of breast cancer patients that could be responsive to combined targeted therapies. The CELsignia Multi-Pathway Signaling Function (CELsignia) Test uses an impedance biosensor to quantify an individual patient’s ex vivo live tumor cell signaling response in real-time to specific HER family and c-Met co-stimulation and targeted therapies. RESULTS: The test identified breast tumors with hyperactive HER1, HER2, HER3/4, and c-Met coordinated signaling that express otherwise normal amounts of these receptors. The supporting data of the pre-clinical verification of this test included analyses of 79 breast cancer patients’ cell response to HER and c-Met agonists. The signaling results were confirmed using clinically approved matching targeted drugs, and combinations of targeted drugs in addition to correlative mouse xenograft tumor response to HER and c-Met targeted therapies. CONCLUSIONS: The results of this study demonstrated the potential benefit of a functional test for identifying a subpopulation of breast cancer patients with coordinated abnormal HER and c-Met signaling for a clinical trial testing combination targeted therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-021-00798-9. BioMed Central 2022-01-08 /pmc/articles/PMC8742957/ /pubmed/34998412 http://dx.doi.org/10.1186/s12964-021-00798-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
MacNeil, Ian A.
Khan, Salmaan A.
Sen, Adrish
Soltani, Sajjad M.
Burns, David J.
Sullivan, Brian F.
Laing, Lance G.
Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
title Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
title_full Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
title_fullStr Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
title_full_unstemmed Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
title_short Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
title_sort functional signaling test identifies her2 negative breast cancer patients who may benefit from c-met and pan-her combination therapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742957/
https://www.ncbi.nlm.nih.gov/pubmed/34998412
http://dx.doi.org/10.1186/s12964-021-00798-9
work_keys_str_mv AT macneiliana functionalsignalingtestidentifiesher2negativebreastcancerpatientswhomaybenefitfromcmetandpanhercombinationtherapy
AT khansalmaana functionalsignalingtestidentifiesher2negativebreastcancerpatientswhomaybenefitfromcmetandpanhercombinationtherapy
AT senadrish functionalsignalingtestidentifiesher2negativebreastcancerpatientswhomaybenefitfromcmetandpanhercombinationtherapy
AT soltanisajjadm functionalsignalingtestidentifiesher2negativebreastcancerpatientswhomaybenefitfromcmetandpanhercombinationtherapy
AT burnsdavidj functionalsignalingtestidentifiesher2negativebreastcancerpatientswhomaybenefitfromcmetandpanhercombinationtherapy
AT sullivanbrianf functionalsignalingtestidentifiesher2negativebreastcancerpatientswhomaybenefitfromcmetandpanhercombinationtherapy
AT lainglanceg functionalsignalingtestidentifiesher2negativebreastcancerpatientswhomaybenefitfromcmetandpanhercombinationtherapy